MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity

Cell Cycle

Volumn 10, Issue 18, 2011, Pages 3176-3188

  Stindt, Maren H ^a   Carter, Stephanie ^a   Vigneron, Arnaud M ^a   Ryan, Kevin M ^a   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

ARF; L11; MDM2; p53; SUMO 2 3; SUMOylation

Indexed keywords

ARF PROTEIN; NEDD8 PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RING FINGER PROTEIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UBIQUITIN;

ARTICLE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOLUS; PROTEIN BINDING; PROTEIN EXPRESSION; RING FINGER MOTIF; SUMOYLATION; UBIQUITINATION;

EID: 80052899294     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.18.17436     Document Type: Article

References (89)

1. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; DOI:10.1016/j.cell.2009.04.037.
2. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21; PMID:1552940; DOI:10.1038/ 356215a0.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; DOI:10.1126/science.1905840.
4. 1 arrest and apoptosis. Cancer Res 1994; 54:1169-74; PMID:8118801.
5. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9; PMID:7834749; DOI:10.1016/0092-8674(95)90412-3.
6. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683-94; PMID:11463392; DOI:10.1016/S1097-2765(01)00214-3.
7. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003; 10:404-8; PMID:12719716; DOI:10.1038/sj.cdd.4401191.
8. 2/M Promoters. Mol Cell Biol 2005; 25:3737-51; PMID:15831478; DOI:10.1128/MCB.25.9.3737-51.2005.
9. Böhlig L, Rother K. One Function-Multiple Mechanisms: The Manifold Activities of p53 as a Transcriptional Repressor. J Biomed Biotechnol 2011; 2011:464916; PMID:21436991; DOI:10.1155/2011/464916.
10. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, et al. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999; 274:29677-82; PMID:10514438; DOI:10.1074/jbc.274.42.29677.
11. Krause K, Wasner M, Reinhard W, Haugwitz U, Dohna CL, Mossner J, et al. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000; 28:4410-8; PMID:11071927; DOI:10.1093/nar/28.22.4410.
12. 1 levels in a human carcinoma cell line. Br J Cancer 2000; 82:642-50; PMID:10682678.
13. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9; PMID:9153395; DOI:10.1038/387296a0.
14. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303; PMID:9153396; DOI:10.1038/387299a0.
15. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206-8; PMID:7477327; DOI:10.1038/378206a0.
16. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-6; PMID:7477326; DOI:10.1038/378203a0.
17. Alarcon-Vargas D, Ronai Z. p53-Mdm2 - the affair that never ends. Carcinogenesis 2002; 23:541-7; PMID:11960904; DOI:10.1093/carcin/23.4.541.
18. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4:793-805; PMID:15510160; DOI:10.1038/nrc1455.
19. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1:1017-26; PMID:14707285.
20. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003; 3:577-87; PMID:12842086; DOI:10.1016/S1535-6108(03)00134-X.
21. Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999; 18:22-7; PMID:9878046; DOI:10.1093/emboj/18.1.22.
22. Gu J, Nie L, Wiederschain D, Yuan ZM. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol Cell Biol 2001; 21:8533-46; PMID:11713288; DOI:10.1128/MCB.21.24.8533-46.2001.
23. Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 2001; 21:8521-32; PMID:11713287; DOI:10.1128/MCB.21.24.8521-32.2001.
24. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60; PMID:8479525; DOI:10.1038/362857a0.
25. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004; 118:83-97; PMID:15242646; DOI:10.1016/j.cell.2004.06.016.
26. Liu G, Xirodimas DP. NUB1 promotes cytoplasmic localization of p53 through cooperation of the NEDD8 and ubiquitin pathways. Oncogene 2010; 29:2252-61; PMID:20101219; DOI:10.1038/onc.2009.494.
27. Chen L, Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 2003; 22:5348-57; PMID:12917636; DOI:10.1038/sj.onc.1206851.
28. ARF-mediated SUMO-conjugation and degradation. Cell Cycle 2009; 8:3537-43; PMID:19829080; DOI:10.4161/cc.8.21.9954.
29. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach DA. M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem 2004; 279:27233-8; PMID:15123604; DOI:10.1074/jbc.M402273200.
30. Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun 2005; 337:517-20; PMID:16198310; DOI:10.1016/j.bbrc.2005.09.090.
31. Ayaydin F, Dasso M. Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol Biol Cell 2004; 15:5208-18; PMID:15456902; DOI:10.1091/mbc.E04- 07-0589.
32. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 2000; 275:6252-8; PMID:10692421; DOI:10.1074/jbc.275.9.6252.
33. Tempé D, Piechaczyk M, Bossis G. SUMO under stress. Biochem Soc Trans 2008; 36:874-8; PMID:18793154; DOI:10.1042/BST0360874.
34. Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 2010; 428:133-45; PMID:20462400; DOI:10.1042/BJ20100158.
35. Stehmeier P, Muller S. Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair (Amst) 2009; 8:491-8; PMID:19213614; DOI:10.1016/j.dnarep.2009.01.002.
36. Melchior F, Hengst L. SUMO-1 and p53. Cell Cycle 2002; 1:245-9; PMID:12429940; DOI:10.4161/cc.1.4.131.
37. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999; 18:6455-61; PMID:10562557; DOI:10.1093/emboj/18.22.6455.
38. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 1999; 18:6462-71; PMID:10562558; DOI:10.1093/emboj/18.22.6462.
39. Schmidt D, Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA 2002; 99:2872-7; PMID:11867732; DOI:10.1073/pnas.052559499.
40. Kwek SS, Derry J, Tyner AL, Shen Z, Gudkov AV. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 2001; 20:2587-99; PMID:11420669; DOI:10.1038/sj.onc.1204362.
41. Wu SY, Chiang CM. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J 2009; 28:1246-59; PMID:19339993; DOI:10.1038/emboj.2009.83.
42. Cheema A, Knights CD, Rao M, Catania J, Perez R, Simons B, et al. Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD. J Cell Physiol 2010; 225:371-84; PMID:20458745; DOI:10.1002/jcp.22224.
43. Weger S, Hammer E, Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett 2005; 579:5007-12; PMID:16122737; DOI:10.1016/j.febslet.2005.07.088.
44. Bischof O, Schwamborn K, Martin N, Werner A, Sustmann C, Grosschedl R, et al. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 2006; 22:783-94; PMID:16793547; DOI:10.1016/j.molcel.2006. 05.016.
45. Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene 2011; 30:1108-16; PMID:20972456; DOI:10.1038/onc.2010.462.
46. Pennella MA, Liu Y, Woo JL, Kim CA, Berk AJ. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J Virol 2010; 84:12210-25; PMID:20861261; DOI:10.1128/JVI.01442-10.
47. Li T, Santockyte R, Shen RF, Tekle E, Wang G, Yang DC, et al. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J Biol Chem 2006; 281:36221-7; PMID:17012228; DOI:10.1074/jbc.M608236200.
48. Chang PC, Izumiya Y, Wu CY, Fitzgerald LD, Campbell M, Ellison TJ, et al. Kaposi's sarcoma associated herpesvirus (KSHV) encodes a SUMO E3 ligase which is SIM-dependent and SUMO-2/3-specific. J Biol Chem 2010; 285:5266-73; PMID:20034935; DOI:10.1074/jbc.M109.088088.
49. Böttger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999; 18:189-99; PMID:9926934; DOI:10.1038/sj.onc.1202281.
50. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999; 447:5-9; PMID:10218570; DOI:10.1016/S0014-5793(99)00254-9.
51. Badciong JC, Haas AL. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002; 277:49668-75; PMID:12393902; DOI:10.1074/jbc.M208593200.
52. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N, et al. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 2007; 26:90-101; PMID:17170710; DOI:10.1038/sj.emboj.7601465.
53. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945-51; PMID:10722742; DOI:10.1074/jbc.275.12.8945.
54. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 2003; 23:4939-47; PMID:12832479; DOI:10.1128/MCB.23.14.4939-47.2003.
55. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH, et al. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 2003; 23:4929-38; PMID:12832478; DOI:10.1128/MCB.23.14.4929-38.2003.
56. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8; PMID:14704432; DOI:10.1126/science.1092472.
57. Kitagaki J, Agama KK, Pommier Y, Yang Y, Weissman AM. Targeting tumor cells expressing p53 with a watersoluble inhibitor of Hdm2. Mol Cancer Ther 2008; 7:2445-54; PMID:18723490; DOI:10.1158/1535-7163.MCT-08-0063.
58. Desterro JM, Thomson J, Hay RT. Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett 1997; 417:297-300; PMID:9409737; DOI:10.1016/S0014-5793(97)01305-7.
59. Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 2001; 276:12654-9; PMID:11124955; DOI:10.1074/jbc.M009476200.
60. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 2001; 276:35368-74; PMID:11451954; DOI:10.1074/jbc.M104214200.
61. Ulrich HD. The fast-growing business of SUMO chains. Mol Cell 2008; 32:301-5; PMID:18995828; DOI:10.1016/j.molcel.2008.10.010.
62. Kuo ML, den Besten W, Thomas MC, Sherr CJ. Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle 2008; 7:3378-87; PMID:18948745; DOI:10.4161/cc.7.21.6930.
63. ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle 2005; 4:597-603; PMID:15876874; DOI:10.4161/cc.4.4.1588.
64. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol 2000; 2:179-81; PMID:10707090; DOI:10.1038/35004057.
65. Carter S, Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008; 7:2519-28; PMID:18719371; DOI:10.4161/cc.7.16.6422.
66. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25; PMID:8242752; DOI:10.1016/0092-8674(93)90500-P.
67. Deng Z, Wan M, Sui G. PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol 2007; 27:3780-92; PMID:17353273; DOI:10.1128/MCB.01761-06.
68. Azuma Y, Arnaoutov A, Dasso M. SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol 2003; 163:477-87; PMID:14597774; DOI:10.1083/jcb.200304088.
69. Lo D, Lu H. Nucleostemin: Another nucleolar "Twister" of the p53-MDM2 loop. Cell Cycle 2010; 9:3227-32; PMID:20703089; DOI:10.4161/cc.9.16. 12605.
70. Nishida T, Yamada Y. The nucleolar SUMO-specific protease SMT3IP1/SENP3 attenuates Mdm2-mediated p53 ubiquitination and degradation. Biochem Biophys Res Commun 2011; 406:285-91; PMID:21316347; DOI:10.1016/j.bbrc.2011.02.034.
71. Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 2010; 9:472-8; PMID:20081365; DOI:10.4161/cc.9.3.10556.
72. Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, Lamond AI. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol Cell Proteomics 2006; 5:2298-310; PMID:17000644; DOI:10.1074/mcp.M600212-MCP200.
73. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I. Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem 2006; 281:16117-27; PMID:16524884; DOI:10.1074/jbc.M512757200.
74. Vertegaal AC. SUMO chains: polymeric signals. Biochem Soc Trans 2010; 38:46-9; PMID:20074033; DOI:10.1042/BST0380046.
75. Heo KS, Lee H, Nigro P, Thomas T, Le NT, Chang E, et al. PKC{zeta} mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J Cell Biol 2011; 193:867-84; PMID:21624955; DOI:10.1083/jcb.201010051.
76. Chupreta S, Holmstrom S, Subramanian L, Iniguez-Lluhi JA. A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties. Mol Cell Biol 2005; 25:4272-82; PMID:15870296; DOI:10.1128/MCB.25.10.4272-82.2005.
77. Garcia-Dominguez M, Reyes JC. SUMO association with repressor complexes, emerging routes for transcriptional control. Biochim Biophys Acta 2009; 1789:451-9; PMID:19616654.
78. Huang B, Vassilev LT. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3. Aging 2009; 1:845-54; PMID:20157557.
79. Krummel KA, Lee CJ, Toledo F, Wahl GM. The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 2005; 102:10188-93; PMID:16006521; DOI:10.1073/pnas.0503068102.
80. Mauri F, McNamee LM, Lunardi A, Chiacchiera F, Del Sal G, Brodsky MH, et al. Modification of Drosophila p53 by SUMO modulates its transactivation and proapoptotic functions. J Biol Chem 2008; 283:20848-56; PMID:18492669; DOI:10.1074/jbc.M710186200.
81. Yuan H, Zhou J, Deng M, Liu X, Le Bras M, de The H, et al. Small ubiquitin-related modifier paralogs are indispensable but functionally redundant during early development of zebrafish. Cell Res 2010; 20:185-96; PMID:19704416; DOI:10.1038/cr.2009.101.
82. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol 2007; 27:8284-95; PMID:17908790; DOI:10.1128/MCB.00050-07.
83. Carter S, Bischof O, Dejean A, Vousden KH. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 2007; 9:428-35; PMID:17369817; DOI:10.1038/ncb1562.
84. Chen J, Lin J, Levine AJ. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1995; 1:142-52; PMID:8529093.
85. Bálint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene 1999; 18:3923-9; PMID:10435614; DOI:10.1038/sj.onc.1202781.
86. Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139:1327-41; PMID:20064378; DOI:10.1016/j.cell.2009.11.026.
87. Kubbutat MH, Ludwig RL, Levine AJ, Vousden KH. Analysis of the degradation function of Mdm2. Cell Growth Differ 1999; 10:87-92; PMID:10074902.
88. Cesková P, Chichger H, Wallace M, Vojtesek B, Hupp TR. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. J Mol Biol 2006; 357:442-56; PMID:16438982; DOI:10.1016/j.jmb.2005.12.026.
89. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-14; PMID:9724636; DOI:10.1093/emboj/17.17.5001.